垂体催乳素腺瘤的规范化诊疗——垂体协会2023版国际共识解读  

Standardized diagnosis and treatment of pituitary prolactin-secreting adenoma:interpretation of 2023 Pituitary Society international consensus statement

作　　者：刘宇珂 谭惠文[1,2] Cholekho Sumita LIU Yuke;TAN Huiwen;Cholekho Sumita(Department of Endocrinology&Metabolism,West China Hospital,Sichuan University,Chengdu,Sichuan 610041,P.R.China;Center of Pituitary Adenoma and Related Diseases,West China Hospital,Sichuan University,Chengdu,Sichuan 610041,P.R.China)

机构地区：[1]四川大学华西医院内分泌代谢科,成都610041 [2]四川大学华西医院垂体瘤及相关疾病诊疗中心,成都610041

出　　处：《华西医学》2023年第12期1801-1806,共6页West China Medical Journal

基　　金：四川省科学技术厅重点研发项目(2023YFS0259)。

摘　　要：2023年9月5日垂体协会发布垂体催乳素腺瘤(prolactin-secreting adenoma,PRLoma)诊断和管理的国际共识,为垂体PRLoma的筛查、诊疗管理提供了基于最新循证证据的建议。此共识除了对垂体PRLoma临床流行病学、发病机制、临床症状、并发症、诊断要点与治疗进展进行了更新,还重点关注特殊人群如孕妇、绝经后女性、儿童/青少年、跨性别患者,以及特殊类型如囊性、侵袭性垂体PRLoma的治疗。该文通过对共识的更新部分进行解读,希望有助于神经外科和内分泌代谢科医生及相关专业医护人员对PRLoma的规范化诊疗。Pituitary Society released an international consensus statement on the diagnosis and management of prolactin-secreting adenoma(PRLoma)on September 5,2023,providing recommendations based on the latest evidence-based approach for the screening,diagnosis,treatment and management of PRLoma.This consensus statement not only updated the clinical epidemiology,pathogenesis,clinical symptoms,complications,diagnostic criteria,and treatment progress of pituitary PRLoma,but also focused on special populations such as pregnant women,postmenopausal women,children/adolescents,transgender patients,as well as the treatment of special types such as cystic and invasive pituitary PRLoma.This article aims to help neurosurgeons,endocrinologists,and related healthcare professionals standardize the diagnosis and treatment of PRLoma by interpreting the updated section of the consensus.

关 键 词：垂体瘤 高催乳素血症 催乳素腺瘤 诊断 治疗 指南解读 

分 类 号：R736.4[医药卫生—肿瘤]